Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Oral Probiotic Bifidobacterium Longum Supplementation Improves Metabolic Parameters and Alters the Expression of the Renin-Angiotensin System in Obese Mice Liver

  • 2020-07-23
  • Biological Research For Nursing 23(1)
    • A. S. Machado
    • J. R. Oliveira
    • D. F. Lelis
    • A. D. de Paula
    • A. Guimarães
    • J. Andrade
    • I. Brandi
    • S. Santos

Abstract

Background: Obesity and non-alcoholic fatty liver disease (NAFLD) have been increasing at an alarming rate worldwide. Bifidobacterium longum (BL), a common member of the human gut microbiota, has important health benefits through several mechanisms.

Objectives: We evaluated the BL supplementation effects on body metabolism and renin-angiotensin components hepatic expression in mice fed a high-fat diet.

Methods: Thirty-two male mice were divided into four groups: standard diet + placebo (ST), standard diet + Bifidobacterium longum (ST + BL), high-fat diet + placebo (HFD) and high-fat diet + Bifidobacterium longum (HFD + BL). Following the obesity induction period, the ST + BL and HFD + BL groups were supplemented with Bifidobacterium longum for 4 weeks. Then, body, biochemical, histological and molecular parameters were evaluated.

Results: HFD + BL mice had a significant decrease in adipose tissue mass and blood glucose levels, as well as a significant reduction in blood glucose during an intraperitoneal glucose tolerance test. The treatment also resulted in reduced levels of total cholesterol and hepatic fat accumulation. Moreover, we observed an increase in angiotensin converting enzyme 2 (ACE2) and Mas receptor (MASR) expression levels in BL-treated obese mice.

Conclusions: These data demonstrate that BL may have the potential to prevent obesity and NAFLD by modulating the mRNA expression of renin-angiotensin system components.

Keywords: gut microbiota; non-alcoholic fatty liver disease; obesity; renin-angiotensin system.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium longum BL03Improved Glucose ToleranceBeneficial
Moderate
Bifidobacterium longum BL03Increased ACE2 Protein ExpressionBeneficial
Small
Bifidobacterium longum BL03Increased MASR ExpressionBeneficial
Small
Bifidobacterium longum BL03Reduced Adipose Tissue MassBeneficial
Moderate
Bifidobacterium longum BL03Reduced Blood Glucose LevelsBeneficial
Moderate
Bifidobacterium longum BL03Reduced Hepatic Fat AccumulationBeneficial
Moderate
Bifidobacterium longum BL03Reduced Total Cholesterol LevelsBeneficial
Moderate
Bifidobacterium longum MAK34B12LImproved Glucose ToleranceBeneficial
Moderate
Bifidobacterium longum MAK34B12LIncreased ACE2 Protein ExpressionBeneficial
Small
Bifidobacterium longum MAK34B12LIncreased MASR ExpressionBeneficial
Small
Bifidobacterium longum MAK34B12LReduced Adipose TissueBeneficial
Moderate
Bifidobacterium longum MAK34B12LReduced Blood Glucose LevelsBeneficial
Moderate
Bifidobacterium longum MAK34B12LReduced Hepatic Fat AccumulationBeneficial
Moderate
Bifidobacterium longum MAK34B12LReduced Total Cholesterol LevelsBeneficial
Moderate
Back to top